Tag: Medtronic

Omar Ishrak to step down as Medtronic CEO next year

Omar Ishrak, Medtronic’s chairman and CEO is to retire on 26 April 2020, following the end of the company’s current fiscal year. Also, the...

Non-thermal techniques for treatment of venous ulcers: Off-label use of cyanoacrylate...

At the American Venous Forum (AVF; 20–23 February, Tucson, USA), a session on venous leg ulcers turned to possible future treatment strategies as Kathleen...

IDE study to evaluate Abre Venous Self-Expanding Stent in patients with...

Medtronic has announced the initiation of its investigational device exemption (IDE) study for the Abre venous self-expanding stent system. The ABRE IDE Study will...

Medtronic receives favourable CMS ruling on VenaSeal

The US Centers for Medicare and Medicaid Services (CMS) has posted the 2018 Medicare Physician Fee Schedule (CMS-1678-F) and Hospital Outpatient Prospective Payment and...

Medtronic launches Concerto 3D detachable coil system in USA and Europe

Medtronic is expanding its embolisation product portfolio with the launch of the Concerto 3D detachable coil system. The system was launched at the Cardiovascular...

Adhesive closure “an effective add-on” to thermal ablation

Endovenous adhesive closure systems are a useful adjunct to thermal ablation treatment for varicose veins, but it is vital that the possible side-effects of...

VeClose trial indicates 24-month non-inferiority of VenaSeal versus radiofrequency ablation

Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using...

WAVES trial shows 100% vein closure at one month with short...

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...